By Carlo Martuscelli

Indivior PLC (INDV.LN) said Thursday that its U.S. subsidiary, Indivior Inc, has filed new lawsuits against a number of pharmaceutical companies over patent infringements relating to generic versions of its opioid disorder treatment, Suboxone.

The U.K.-listed pharmaceutical company said that it has brought suits against Dr. Reddy's Laboratories Ltd. (RDY), Actavis, Par Pharmaceutical Cos., Alvogen and Teva Pharmaceutical Industries Ltd. (TEVA.TV).

The suits maintain that these companies are infringing its U.S. patent No. 9,931,305, which was issued on April 3. This is not the first instance of patent litigation it's brought against these companies, Indivior said.

Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com

(END) Dow Jones Newswires

April 05, 2018 02:34 ET (06:34 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Teva Pharmaceutical Indu... Charts.
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Teva Pharmaceutical Indu... Charts.